Lp(a) Test at Home

What It Measures

Lp(a) is measured in mg/dL or nmol/L (nmol/L is preferred because Lp(a) particle size varies and mg/dL concentrations are less accurate — confirm which unit your provider uses). Lp(a) is structurally similar to LDL but contains an additional protein called apolipoprotein(a) [apo(a)], which is bound to ApoB-100. Apo(a) structurally resembles plasminogen, which may explain why elevated Lp(a) is associated with both atherosclerosis and thrombosis risk.

Reference ranges (ESC/EAS 2019, PMID: 31504418; EAS 2022 consensus, PMID: 36036785): Optimal <30 mg/dL (<75 nmol/L); borderline 30–50 mg/dL (75–125 nmol/L); elevated >50 mg/dL (>125 nmol/L) — ESC/EAS guideline threshold for aggressive lipid management.

Unit conversion note: 1 nmol/L ≈ 0.4 mg/dL (approximate; varies by apo(a) isoform). Many US labs report in mg/dL; European guidelines and research increasingly use nmol/L.

Why It Matters for Longevity

Lp(a) is estimated to be genetically determined in approximately 90% of its variance — meaning diet, exercise, and most standard lipid-lowering therapies have minimal effect on it. Statins may modestly increase Lp(a) levels in some patients, which is a counterintuitive effect that underscores the importance of knowing your Lp(a) before interpreting an apparent statin non-response.

The 2022 European Atherosclerosis Society consensus (Kronenberg F et al., Eur Heart J, 2022, PMID: 36036785) stated: 'We recommend measuring Lp(a) at least once in every adult's lifetime.' This recommendation is based on consistent Mendelian randomization evidence that elevated Lp(a) is a causal risk factor for cardiovascular disease and aortic stenosis — not just a marker.

Approximately 20% of the global population (roughly 1 in 5 adults) has Lp(a) above 50 mg/dL (125 nmol/L). Most of these individuals do not know it. A family history of premature cardiovascular disease (heart attack before age 60 in a first-degree relative) is a strong predictor of elevated Lp(a).

Current treatment limitations: As of early 2026, no broadly approved Lp(a)-specific therapy exists in the US. PCSK9 inhibitors modestly reduce Lp(a) (20–30%). RNA-based therapies targeting Lp(a) (including olpasiran and pelacarsen) are in Phase 3 trials as of 2024 — a significant development for future clinical management. Knowing your Lp(a) informs risk stratification for more aggressive LDL-C and blood pressure management in high-risk patients.

Top Providers Compared

Ulta Lab Tests — Lipoprotein(a) (~$39–59 verify on site): venipuncture, 1–2 days, CLIA-certified (LabCorp).

Walk-In Lab — Lp(a) (~$49 verify on site): venipuncture, 1–2 days, CLIA-certified (Quest). No affiliate.

LetsGetChecked (check Advanced Heart Panel, ~$129+ verify on site): dried blood spot, 2–5 days, CLIA-certified. Note: Verify whether LetsGetChecked's current panels include Lp(a) standalone — it may be bundled into a more expensive advanced cardiovascular panel.

Pricing note: Lp(a) testing is one of the most affordable at-home specialty cardiovascular tests via Ulta Lab Tests or Walk-In Lab.

How to Interpret Your Results

This is a general reference framework. Lp(a) interpretation requires clinical context — particularly important because there are currently limited treatment options.

Lp(a) below 30 mg/dL (75 nmol/L): Low Lp(a)-specific cardiovascular risk. Standard cardiovascular risk management applies.

Lp(a) 30–50 mg/dL (75–125 nmol/L): Borderline. Warrants attention alongside other cardiovascular risk factors. More aggressive LDL-C and blood pressure management may be appropriate.

Lp(a) above 50 mg/dL (125 nmol/L): ESC/EAS threshold for significantly elevated Lp(a). Physician consultation recommended to contextualize this finding within your overall cardiovascular risk.

Genetic nature of Lp(a): A single lifetime measurement is generally sufficient for most adults, as Lp(a) is highly stable over time and does not respond significantly to lifestyle changes. Retesting is only warranted if enrolled in a clinical trial of an Lp(a)-lowering therapy.

Talk to your doctor: Elevated Lp(a) is an important finding that should be documented in your medical record and reviewed alongside your lipid panel, blood pressure, and family history.

Sample Prep and Accuracy Notes

Fasting required? Fasting is not strictly required for Lp(a) — Lp(a) concentrations are not significantly affected by food intake. However, if you are ordering Lp(a) alongside a lipid panel or fasting glucose, overnight fasting is required for those co-ordered markers.

Assay methodology — nmol/L vs. mg/dL: Lp(a) particle concentration measured in nmol/L is preferred over mass-based mg/dL measurements because Lp(a) particle size varies by apo(a) isoform. Many US labs still report in mg/dL. If possible, request nmol/L units from a certified cardiovascular lab.

Medications and Lp(a): PCSK9 inhibitors (evolocumab, alirocumab) reduce Lp(a) by approximately 20–30%; statins may paradoxically increase Lp(a) by 10–15% in some patients; niacin reduces Lp(a) by 20–30%, but cardiometabolic outcomes data in niacin trials have not shown clinical benefit; estrogen therapy (women) lowers Lp(a).

Frequently Asked Questions

Why isn't Lp(a) on my standard cholesterol test? Standard lipid panels do not include Lp(a). This is a clinical gap that multiple cardiovascular professional organizations have pointed out. Historically, there was no actionable treatment for elevated Lp(a), which reduced the rationale for routine screening. As Lp(a)-specific therapies advance in clinical trials, this is changing.

Can I lower my Lp(a)? Lp(a) is approximately 90% genetically determined and does not respond significantly to diet, exercise, or standard statin therapy. PCSK9 inhibitors offer a modest 20–30% reduction. RNA-based therapies (olpasiran, pelacarsen) in Phase 3 trials as of 2024 show 80–90%+ Lp(a) reduction — if approved, this will change the management landscape.

If my Lp(a) is high, what should I do? Share the result with your physician. In the absence of a specific Lp(a)-lowering therapy, management focuses on aggressively controlling other modifiable risk factors — LDL-C, blood pressure, blood glucose, smoking cessation, and weight management.

Does elevated Lp(a) run in families? Yes. Lp(a) levels are strongly heritable. First-degree relatives of someone with elevated Lp(a) have a significantly higher probability of also having elevated Lp(a). Family cascade testing is an increasingly discussed strategy in cardiovascular prevention.

Should I test Lp(a) if I'm already on a statin? Knowing your Lp(a) is useful even on statin therapy — statins may modestly raise Lp(a), and elevated Lp(a) helps explain residual cardiovascular risk despite LDL-C control.

References

1. Mach F et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2020;41(1):111-188. PMID: 31504418.

2. Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. PMID: 36036785.